In polychemotherapy the combination of drugs is generally based on clinical experience. From the experimental point of view there is only limited knowledge on the rationale for commonly used combinations. The present study was designed to investigate the interaction of two antineoplastic drugs which are often applied in combination. Adriamycin (ADR) and cyclophosphamide (CYC) were tested on the permanent human mammary carcinoma cell line EFM 149. The inhibition of proliferation was measured by cell counts after incubation periods of I to 9 days. A 50% inhibition was defined by the reduced increase of cell number in treated cultures versus control cultures. The ID50 after an incubation of 3 days was determined at 0.O5~g/ml ADR or 0,42~g/ml Cu (in its activated from). When the time of incubation was extended up to 9 days, the ID50 of ADR decreased in a time-dependent manner to 0,0085Ng/ml where as the ID50 of CYC was constant. In a second series of experiments ADR and CYC were applied in varying combinations. An inhibition by 75% was achieved by the following combinations during the 3-day treatment schedule: Oncol. 21, 531, 1985) . Throughout the present investigations aYew oral formulation of zindoxifene was used. The bioavailabillty of this new form was considerably improved over previous preparations. Dose-response relationship studies were carried out using the DMBA-induced, autochthonous mammary carcinoma in rats and a standard 28 days treatment. The optimal dose of zindoxifene was found to be 10 mg/kg body weight. Under identical experimental conditions equimolar doses of tamoxifen citrate were less active. When suboptimal doses of both tamoxifen and zindoxifene were administered simultaneously, neither additive nor synergistic effects were observed. The antiestrogenic activity of zindoxifene was confirmed by the inhibition of the uterotrophic action of 17-8-estradiol in infantile rats. In contrast, high doses stimulated uterine growth indicating that the compound has some remaining estrogen activity. Acute and subacute toxicity studies in rats revealed that pharmacologically active zindoxifene doses were well tolerated even when administered daily over a period of 13 weeks. The pharmacological and toxicological profile of zindoxifene suggests that clinical studies are warranted.
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